Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04515576 | A Study of LY3493269 in Participants With Type 2 Diabetes | PHASE1 | COMPLETED | 56 | — | — | Aug 25, 2020 | Mar 9, 2021 | Jan 14, 2025 | 3 | United States |
TEAE is an untoward medical occurrence that emerges during a defined treatment period, having been absent pretreatment, or worsens relative to the pretreatment state, and does not necessarily have to have a causal relationship with this treatment. An SAE is defined as any untoward medical occurrence that, at any dose: 1. Results in death 2. Is life-threatening 3. Requires inpatient hospitalization or prolongation of existing hospitalization 4. Results in persistent disability/incapacity 5. Is a congenital anomaly/birth defect 6. Other situations: Based on medical or scientific judgement. A summary of SAEs, TEAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| 1.5 milligrams (mg) Dulaglutide | ACTIVE_COMPARATOR | Participants received 1.5 mg dulaglutide subcutaneously (SC) once weekly (QW) for 4 weeks. |
| 0.3 mg LY3493269 | EXPERIMENTAL | Participants received 4 fixed dosed of 0.3 mg LY3493269 SC QW for 4 weeks. |
| 1 mg LY3493269 | EXPERIMENTAL | Participants received 4 fixed dosed of 1 mg LY3493269 SC QW for 4 weeks. |
| 0.75/1.5/3 mg LY3493269 | EXPERIMENTAL | Participants received LY3493269 0.75 mg on week 1, 1.5 mg on week 2 and 3 mg on week 3 and 4 SC as weekly doses. |
| 1.5/3/4/5 mg LY3493269 | EXPERIMENTAL | Participants received LY3493269 1.5 mg on week 1, 3 mg on week 2, 4 mg on week 3 and 5 mg on week 4 as weekly doses. |
| Placebo | PLACEBO_COMPARATOR | Participants received placebo subcutaneously (SC) once weekly (QW) for 4 weeks. |
| Name | Type | Description |
|---|---|---|
| LY3493269 | DRUG | Administered SC |
| Dulaglutide | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Are male or female not of childbearing potential * Have a body mass index of 23 to 50 kilograms per square meter (kg/m²), inclusive, at screening * Have had a stable body weight (\<5% body weight change) for the 3 months prior to screening * Have not modified their diet or ado...